Communication to Pharmacies: General
- FDA Expands Eligibility for Pfizer-BioNTech COVID-19 Vaccine Booster Dose to Children 5 through 11 Years
May 2022 - COM-2022-013-Comunicado MCS a Farmacias sobre uso de Invermectin -versión español
- COM-2022-013-Comunicado MCS a Farmacias sobre uso de Invermectin -versión inglés
- COM-2021 – 59 Operational Guide for the submission of the transaction COVID -19 – Oral antiviral drugs emergency use
- Comunicado a Farmacias Ley -142-2020
- COM-2021-053- LEY NUM. 35 2021
- FDA Expands EUAs of Moderna’s and J&J’s COVID-19 Vaccines
November 2021 - FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine for Emergency Use in Children 5 through 11 Years of Age
November 2021
- Prior-authorization for Ivermectin due to Increased Use during COVID-19
September 2021 - Comunicado– Carta Normativa-2021-301-D
April 2021 - COVID-19 Vaccine administration requirements
January 2021 - Billing of Insulins Pens
November 2020 - Educational bulletin of the Pharmacy Audit process
November 2020 - Final Rule Modification of the Requirements for the Use of HIPAA National Council for Prescription Drug Programs (NCPDP) D.0 Standard
October 2020 - Orden Administrativa Núm. 441 del Departamento de Salud de Puerto Rico
April 2020 - Prior-authorization for hydroxychloroquine and chloroquine follow up after FDA’s drug safety communication
April 2020 - Carta de Clarificación- Medicamento Clopidogrel
April 2020 - Orden Administrativa Núm. 435 del Departamento de Salud de Puerto Rico
April 2020 - Recomendaciones de dispensación
April 2020 - Prior-authorization for hydroxychloroquine and chloroquine
April 2020 - Guía operacional sobre el despacho de medicamentos durante el estado de emergencia debido al COVID-19
Marzo 2020 - Entrega de medicamentos durante el estado de emergencia debido al COVID-19 y la Ley Núm. 19-2020
Marzo 2020 - Despacho de Medicamentos en Situaciones de Emergencia y/o durante Estado de Emergencia – Poveedores Puerto Rico
Marzo 2020 - Comunicado para proveedores sobre Emergencia COVID-19
Marzo 2020 - RE: Carta Normativa ASES 19-0305. Política pública de anti-discrimen a beneficiarios por razón de identidad de género, expresión de género u orientación sexual real o percibida, al solicitar o recibir servicios de salud.
Marzo 2019 - RE: ASES Normative Letter 19-0305. Public policy for non-discrimination to beneficiaries by reason of gender identity, expression of gender or real or perceived sexual orientation, when requesting or receiving health services.
March 2019 - Guía Básica a Proveedores para manejo sensible y adecuado al brindar servicios de salud a beneficiarios LGBTT+
March 2019 - Importance of the credentialization of pharmacies – Puerto Rico
February 2019
Communication to Pharmacies: Safety
- FDA Warns About Possible Increased Risk of Death with Copiktra
July 2022 - FDA Requires Revisions to Warnings for JAK Inhibitors
June 2022 - FDA Investigating Possible Increased Risk of Death with Ukoniq
March 2022 - Buprenorphine Medicines and the Risk of Dental Problems
January 2022 - FDA Requires Revisions to Warnings for JAK Inhibitors
September 2021 - Lamictal Drug Safety Communication
May 2021 - FDA Warns that Abuse and Misuse of Propylhexedrine Causes Serious Harm
March 2021 - Risk of serious heart-related problems and cancer with Xeljanz Xeljanz XR
February 2021
Communication to Pharmacies: Education
- FDA Authorizes Boosters for Moderna and Pfizer Bivalent Vaccine
September 2022 - FDA Authorizes Novavax COVID-19 Vaccine in Adolescents
August 2022 - FDA Authorizes Emergency Use of Novavax COVID-19 Vaccine
July 2022 - FDA Amends Moderna and Pfizer-BioNTech COVID-19 Vaccine’s EUAs to Include Children 6 Months of Age and Older
June 2022 - Update on Heart Failure Guidelines – A Summary
May 2022 - New Indications and First-time Generics Approved by FDA from January 2022 to March 2022
April 2022 - FDA and CDC Recommend Second Booster to Certain Individuals
March 2022 - Summary of Emergency Use Authorizations for COVID-19 Treatment
March 2022
- FDA Grants Full Approval to Moderna’s COVID-19 Vaccine
February 2022 - FDA Issues Back-to-Back EUAs for Oral Treatments for COVID-19
December 2021 - FDA Expands EUAs of Pfizer-BioNTech and Moderna COVID-19 Vaccines
November 2021 - Increased Use of Ivermectin for the Prevention and Treatment of COVID-19
September 2021 - FDA Approves First Covid-19 Vaccine
August 2021 - EUA Amendment for COVID-19 Vaccine in Immunocompromised Individuals
August 2021 - New indications and first-time generics approved by the FDA from January 2021 to March 2021
July 2021 - Emergency use authorization for Sotrovimab for COVID-19
June 2021 - Pharmacists and vaccines
May 2021 - Emergency Use Authorization for COVID-19 Vaccine in Adolescents
May 2021 - FDA and CDC Lift Pause on Johnson Johnson (Janssen) COVID-19 Vaccine Use
April 2021 - Update to ACC Guidelines for Heart Failure Treatment
April 2021 - J&J- Janssen COVID-19 Vaccine Pause in the Use
April 2021 - NCCN Guidance COVID-19 Vaccination in Cancer Patients
March 2021 - Emergency use authorization for third COVID-19 vaccine
March 2o21 - New indications and first-time generics approved by the FDA from October 2020 to December 2020
February 2021 - FDA Statement on Following the Authorized Dosing Schedules for COVID-19 Vaccines
January 2021
PharmNotes
Recalls
- Drug Recall – Insulin glargine-yfgn U-100 3mL Prefilled Pens_Mylan Pharmaceuticals Inc.
July 2022 - Drug Recall – Morphine Sulfate ER 30mg and 60m Tablets_Bryant Ranch Prepack Inc.
June 2022 - Drug Recall: Accupril 10mg, 20mg and 40mg Tablets_Pfizer
April 2022 - Drug Recall: Insulin Glargine 100units/mL_Mylan Pharmaceuticals Inc., a Viatris Company
April 2022 - Drug Recall: Symjepi 0.15mg and 0.3mg_Adamis Pharmaceuticals Corp.
March 2022 - Drug Recall: Orphenadrine 100mg ER tablets_Sandoz Inc.
March 2022 - Drug Recall: Accuretic and Quinapril-Hydrochlorothiazide_Pfizer
March 2022 - Drug Recall – Metformin ER Tablets 750mg – Viona Pharmaceuticals
December 2021
- Drug Recall – Nitroglycerin Lingual Spray 12g – Padagis
December 2021 - Drug Recall – Irbesartan and Irbesartan-Hydrochlorothiazide_Lupin Pharmaceuticals
October 2021 - Drug Recall – Methocarbamol 500mg tablets_Bryant Ranch Prepack
October 2021 - Drug Recall: Firvanq 50mg/ml – Azurity Pharmaceuticals, Inc.
September 2021 - Drug Recall: Ruzurgi 10mg – Jacobus Pharmaceuticals Company, Inc.
September 2021 - Drug Recall: Chantix – Pfizer
July 2021 - Drug Recall: Metformin ER 750mg – Viona Pharmaceuticals Inc
June 2021 - Drug Recall with the Name: Drug Recall: NP Thyroid – Acella Pharmaceuticals LLC
May 2021 - Drug Recall: Guanfacine ER 2mg- – Apotex Corp.
April 2021 - Recall: Telmisartan 20mg – Alembic Pharmaceuticals, Inc.
March 2021 - Drug Recall: Spironolactone – Bryant Ranch Prepack.
March 2021 - Drug Recall: Adam’s Secret Extra Strength – Adamssecret.co
February 2021 - Recall: Enoxaparin Sodium Injection, USP – Apotex Corp.
February 2021 - Drug Recall with the name: Ketorolac 30 mg/mL Injection – Fresenius Kabi
January 2021 - Drug Recall (expansion): Metformin ER 750mg – Nostrum Lab
January 2021 - Drug Recall with the name: Drug Recall (extension): Paroex Chlorhexidine Gluconate Oral 15mL unit dose
January 2021
Join Our Network
- PharmPix Pharmacy Network Request Application
- Exception Request Form
- Important Information About Your Appeal Rights
- Concurrent Utilization Review
- Pharmacy Rights and Responsibilities
- Members Rights and Responsibilities
- Pharmacy and Therapeutics Committee
- Pricing Research Request Form
- Prior Authorization Form
- Retrospective Drug Utilization Review Program
- Universal Claim Form
- Pharmacy Credentialing/ Recredentialing
- PharmPix Pharmacy Network Provider Fraud Waste and Abuse (FWA) and General Compliance Training
- 2022 Fraud, Waste and Abuse (FWA) and General Compliance Training Log
- 2021 Fraud, Waste and Abuse (FWA) and General Compliance Training Log
- Fraud, Waste and/or Abuse Complaint Form
- PharmPix Contact Information
- Provider Complaint Form
- Pharmacy Contracting
- Pharmacy Credentialing Form
- PharmPix Provider Manual